SELLAS Life Sciences reports wider Q1 loss as REGAL Phase 3 AML trial nears key data readout and SLS009 advances in early-line studies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results